NINA SMELLEY: Open Payments
NPI 1275163503 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,584 in 129 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $1,076 · 2025 $1,584
Food & beverage: $1,584
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 28 | $316 |
| Amgen Inc. | 43 | $276 |
| AstraZeneca Pharmaceuticals LP | 10 | $190 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $168 |
| Sumitomo Pharma America, Inc. | 12 | $159 |
| Lilly USA, LLC | 6 | $97 |
| Phathom Pharmaceuticals, Inc. | 5 | $79 |
| ABBVIE INC. | 4 | $68 |
| Xeris Pharmaceuticals, Inc. | 3 | $64 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $53 |
Products named: OTEZLA, Kerendia, GEMTESA, Wegovy, Ozempic, AIRSUPRA, VOQUEZNA, Rybelsus.
Industry payments across AL — which companies pay providers there.
